Evaluation of the Efficacy of Biobran (Rice Bran Arabinoxylan) in Supporting Breast Cancer Chemotherapy
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age20-65
SponsorChina Medical University Hospital
About this trial
This study aims to evaluate the potential supportive effects of rice bran arabinoxylan compound (Biobran) in patients with breast cancer receiving paclitaxel and doxorubicin chemotherapy. The study will assess chemotherapy-related side effects, quality of life, tumor size, tumor antigens, and routine blood test parameters over 24 weeks of treatment.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Breast cancer stage I-III
Disqualifiers
pregnant, lactation, breast recurrence, mental disease, autoimmune disease over hte past 5 years, people who take plant or fungal polysaccharide health supplements
Trial design
Design model
Parallel
Treatments tested in this trial
Biobran supplementation
Dietary supplement3 g Biobran per day for 24 weeks
Treatment groups
96 Participants
are divided into 2 treatment groupsGroup A: PlaceboNo intervention 0 interventions
Group B: BiobranExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Change from baseline in the mean quality of life score at 12 weeks
EORTC QLQ-BR42 scores range from 0 to 100. For symptom scales and single-item measures, higher scores indicate greater symptom burden or more severe problems, whereas lower scores indicate fewer symptoms or problems.
Time frame
Baseline and at 6、12、18、24 weeks after chemotherapySponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov